Core Insights - The article provides an overview of the financing events in the primary market, highlighting a total of 79 financing events this week, with a total financing amount of approximately 6.573 billion yuan, which is an increase of 2.024 billion yuan compared to the previous week [2][3]. Financing Events Summary - This week, there were 56 disclosed financing events, with a notable shift in the financing amount distribution compared to last week. Events under 5 million yuan remained at 2, while those between 5 million and 10 million yuan increased to 28. Events between 10 million and 50 million yuan decreased to 5, while those between 50 million and 100 million yuan decreased to 11. There were 7 events between 100 million and 500 million yuan, an increase of 2, and 2 events between 500 million and 1 billion yuan, an increase of 1. Notably, there was 1 event exceeding 1 billion yuan this week, while there were none last week [3][4]. Notable Investment Events - In the nuclear power sector, the company "聚变能源" announced a strategic financing round of 1.75 billion yuan, led by China National Nuclear Corporation and Zhejiang Energy Power [4]. - In the medical device sector, "帕母医疗" completed a nearly 100 million USD equity financing round, aimed at expanding global clinical trials and overseas business [5]. - The AI large model company "智谱" secured over 1 billion yuan in strategic financing to enhance technology innovation and ecosystem development [5]. - The commercial aerospace company "深蓝航天" completed a B4 round financing of nearly 500 million yuan, focusing on the development of reusable liquid rockets [5]. Industry Distribution - The financing events this week spanned 10 industries, with the top five being information technology, healthcare, equipment manufacturing, electronic information, and electric power equipment and new energy. These five industries accounted for 81.01% of all financing events [9][10]. - In terms of financing amount, the top five industries were electric power equipment and new energy, information technology, healthcare, equipment manufacturing, and electronics, collectively accounting for 95.86% of the total financing amount [11]. Regional Distribution - The top five regions for financing events were Shanghai, Jiangsu, Beijing, Zhejiang, and Guangdong, which together accounted for 72.15% of all financing events. In terms of financing amount, these regions accounted for 93.80% of the total [14][15]. Financing Rounds - The most active financing rounds this week were angel and A rounds, totaling 52 events. Strategic financing ranked third with 10 events. Early-stage financing (A rounds and earlier) accounted for 65.83% of the total events, showing an increase from the previous week [17]. Investment Institutions - A total of 111 investment institutions participated in financing activities this week, with 121 actions recorded. Notably active institutions included 合肥创新投资, 启航投资, and 红杉中国, each participating in 2 events [18]. Exit Situation - There were 29 public exit cases this week, an increase of 6 from the previous week. The exit types included 9 equity transfers, 6 mergers and acquisitions, and 10 new three-board listings, with 4 IPOs occurring this week [21][22].

本轮融资两次超募。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，帕母医疗日前完成近1亿美元C轮融资。本轮融资由启明创投和老股东礼来亚洲 共同领投，现有投资人奥博资本（OrbiMed）、高榕创投超额追加投资。本次募资将主要用来推动 帕母医疗的全球临床、海外业务及战略发展规划。 值得一提的是， 本轮融资两次超募，是近年来亚太地区创新医疗器械领域最大规模的市场化融资 。 帕母医疗的 原研核心技术及产品"经皮肺动脉去神经术（简称PADN）"系列导管和主机是全球首个 中国率先获批上市的肺高压微创介入疗法产品 。肺高压（Pulmonary Hypertension，PH）发展严 重会引起心衰和死亡，被称为"心血管中的癌症"，且治疗手段非常有限，目前以药物为主。PADN用 射频消融术阻断肺血管内膜交感神经，从而有效降低肺动脉压力，延缓疾病进程。 除了在中国开展 相关产品的 商业化进程，帕母医疗在全球还有多个正在进行的临床项目。 在中 国，针对慢性心衰合并2型肺高压适应症的大型注册临床，正在与30多家顶级三甲医院合作进行中， 目前即将收尾。在欧洲、亚洲多家顶尖医 ...

# PA D N 登 陆 欧 美 顶 级 医 疗机构 帕母医疗的原研核心技术及产品 "经皮肺动脉去神经术（简称PADN）"系列导管和主机 是全球首个中国率 先获批上市的肺高压微创介入疗法产品。 肺高压（Pulmonary Hypertension，PH）发展严重会引起心衰和 死亡，被称为"心血管中的癌症"，且治疗手段非常有限，目前以药物为主。PADN用射频消融术阻断肺血 管内膜交感神经，从而有效降低肺动脉压力，延缓疾病进程。 过去8年，帕母医疗PADN相关临床试验每一年都登上全美心血管领域最具影响力的峰会——美国经导管心血 管治疗学术大会（Transcatheter Cardiovascular Therapeutics，TCT），发表超过15篇心血管顶刊论文，包括但 不限于JACC、 EuroInvervention、JACC HF等，这标志着这项中国原创技术已经逐步获得世界肺高压治疗学术 界和临床界的肯定。 2024年10月，帕母医疗一行受邀在美国梅奥诊所（Mayo Clinic）完成了关于帕母医疗的PADN的首次北美临床 培训。作为国际上享有盛誉的顶尖医疗机构，梅奥诊所已经连续六次被《新闻周刊（News ...